PORTFOLIO

Our activities as a dedicated private equity healthcare investor date back to the late 1980s. At that time, providing start-up and growth capital to innovative healthcare companies was not commonplace. In fact, we were one of the first to assume this role. As a result, we have grown to become one of the most experienced healthcare investors in Europe. Over time, we have raised a suite of closed-end investment vehicles that target private companies only, the latest two being LSP 5 and LSP HEF. Combined, we have raised through all our private equity funds more than €1 billion, making it the largest franchise within our firm.
 

Next-generation neo-epitope vaccines and oncolytic viruses visit website

Next generation immuno-modulators acting on adaptive and innate immunity visit website

Therapies for heart failure and related Cardiovascular Diseases visit website

Therapies for lysosomal storage - and protein misfolding diseases visit website

Therapies for autoimmune and immunology related diseases visit website

Development of drugs for orphan diseases

Novel, small insulin patch pump visit website

mRNA immunotherapies for oncology and infectious diseases visit website

Implantable neuro-stimulation system for spinal cord injury visit website

Acquired by Codman Neuro 2017

Innovative devices for minimally invasive stroke therapy
visit website

Acquired by Bruker 2017

Light sheet microscopy
visit website

IPO 2017

Innovative treatments for cancer and other diseases
visit website

IPO 2016

Innovative cancer treatments
visit website

Acquired by Medtronic 2014

Medical device for treatment of Parkinson's disease

Orthobiological products for tissue and fracture repair visit website

IPO 2016

Ultra-rapid diagnosis of infections
visit website

Acquired by GSK 2015

Breakthrough vaccines for infectious diseases
visit website

Acquired by BioMarin 2015

Development of drugs for Duchenne Muscular Dystrophy
visit website

Acquired by Agilent Technologies 2015

Commercialization of medical instruments and laboratory products
visit website

Acquired by Intrexon 2015

Oral delivery of complex biological medicines

IPO 2015

Innovative treatment for blood cancers
visit website

Acquired by Vectura 2014

Novel medical solutions for lung disease
visit website

IPO 2014

Medical device for brain stimulation
visit website

IPO 2014

Development of drugs for Alzheimer's disease
visit website

IPO 2014

Innovative treatments for heart disease

IPO 2014

Innovative cancer treatments
visit website

Acquired by Agenus 2014

Innovative cancer treatments

Acquired by Salix 2013

Novel treatments for specialist care

Acquired by Ipsen 2013

Novel treatment options for pain and inflammation

Acquired by Dr Reddy 2013

Preparation and development of injectable drugs

Acquired by Syngenta 2013

Next-generation crop protection

Acquired by Post foods 2013

Commercialization of probiotic foodbars

Acquired by LDC

Novel drugs for psychiatric disorders
visit website

Acquired by Syngenta 2012

Advanced crop protection technologies

Acquired by Tigenix 2011

Innovative treatments for bowel disorders and other diseases

Acquired by Edwards 2010

Commercialization of cardiovascular monitoring devices

Acquired by C.R. Bard 2010

State-of-the-art medical devices for heart disease

Acquired by Shire 2010

Innovative treatments for bowel disease

IPO 2010

Novel treatment options for diabetes and other diseases
visit website

IPO 2010

Development of drugs for rare and serious diseases
visit website

Acquired by Alpharma

Delivery of advanced drugs through the skin

Acquired by Daiichi Sankyo 2008

Innovative cancer treatments

IPO 2007

Advanced platform technologies to enable the development of drugs
visit website

Acquired by Shire 2006

Development of drug for rare and fatal disease

IPO 2006

Highly specific detection of tumors
visit website

Acquired by Pharming 2006

Products for medical problems associated with aging

Acquired by Astra Zeneca 2006

Innovative cancer treatments

IPO 2000

Development of vaccines

IPO 1999

Commercialization of vaccines for infectious disease

Acquired by Cosmo

Novel drugs for bladder disorders and inflammatory diseases

IPO 2000

Precise identification of diseases and disorders in humans
visit website

IPO 1996

Diagnostics and laboratory testing equipment
visit website

Spontaneous growth of natural heart valves and vessels visit website

Minimally invasive treatment of bone fractures visit website

First treatment healing rotator cuff disease visit website

Ultra-rapid diagnosis of infections visit website

Prevention of drug misadministration at the bedside visit website

Minimally invasive reshaping of heart valve visit website

Treatment of improper fluid balances in the body visit website

Treatment of severe hospitalized Influenza visit website

Development of next generation biobutanol

Next-generation glucose measuring devices visit website

Advanced robotic platforms visit website

Acquired by Leica

Labeling and detection of biological molecules
visit website

Highly innovative repair of damaged knees and spinal discs visit website

Introgene

Merged with U-Bisys into Crucell

Development of vaccines

Ness

Acquired by Bioness

Innovative rehabilitation products

Quadrant

IPO

Drug formulation

Biora

Acquired by Straumann

Commercialization of products used by dentists and oral surgeons

U-Bisys

Merged with Introgene into Crucell

Innovative drug development platform



PORTFOLIO

Our activities as a dedicated private equity healthcare investor date back to the late 1980s. At that time, providing start-up and growth capital to innovative healthcare companies was not commonplace. In fact, we were one of the first to assume this role. As a result, we have grown to become one of the most experienced healthcare investors in Europe. Over time, we have raised a suite of closed-end investment vehicles that target private companies only, the latest two being LSP 5 and LSP HEF. Combined, we have raised through all our private equity funds more than €1 billion, making it the largest franchise within our firm.
 

Next-generation neo-epitope vaccines and oncolytic viruses visit website

Next generation immuno-modulators acting on adaptive and innate immunity visit website

Therapies for heart failure and related Cardiovascular Diseases visit website

Therapies for lysosomal storage - and protein misfolding diseases visit website

Therapies for autoimmune and immunology related diseases visit website

Development of drugs for orphan diseases

Novel, small insulin patch pump visit website

mRNA immunotherapies for oncology and infectious diseases visit website

Implantable neuro-stimulation system for spinal cord injury visit website

Acquired by Codman Neuro 2017

Innovative devices for minimally invasive stroke therapy
visit website

Acquired by Bruker 2017

Light sheet microscopy
visit website

IPO 2017

Innovative treatments for cancer and other diseases
visit website

IPO 2016

Innovative cancer treatments
visit website

Acquired by Medtronic 2014

Medical device for treatment of Parkinson's disease

Orthobiological products for tissue and fracture repair visit website

IPO 2016

Ultra-rapid diagnosis of infections
visit website

Acquired by GSK 2015

Breakthrough vaccines for infectious diseases
visit website

Acquired by BioMarin 2015

Development of drugs for Duchenne Muscular Dystrophy
visit website

Acquired by Agilent Technologies 2015

Commercialization of medical instruments and laboratory products
visit website

Acquired by Intrexon 2015

Oral delivery of complex biological medicines

IPO 2015

Innovative treatment for blood cancers
visit website

Acquired by Vectura 2014

Novel medical solutions for lung disease
visit website

IPO 2014

Medical device for brain stimulation
visit website

IPO 2014

Development of drugs for Alzheimer's disease
visit website

IPO 2014

Innovative treatments for heart disease

IPO 2014

Innovative cancer treatments
visit website

Acquired by Agenus 2014

Innovative cancer treatments

Acquired by Salix 2013

Novel treatments for specialist care

Acquired by Ipsen 2013

Novel treatment options for pain and inflammation

Acquired by Dr Reddy 2013

Preparation and development of injectable drugs

Acquired by Syngenta 2013

Next-generation crop protection

Acquired by Post foods 2013

Commercialization of probiotic foodbars

Acquired by LDC

Novel drugs for psychiatric disorders
visit website

Acquired by Syngenta 2012

Advanced crop protection technologies

Acquired by Tigenix 2011

Innovative treatments for bowel disorders and other diseases

Acquired by Edwards 2010

Commercialization of cardiovascular monitoring devices

Acquired by C.R. Bard 2010

State-of-the-art medical devices for heart disease

Acquired by Shire 2010

Innovative treatments for bowel disease

IPO 2010

Novel treatment options for diabetes and other diseases
visit website

IPO 2010

Development of drugs for rare and serious diseases
visit website

Acquired by Alpharma

Delivery of advanced drugs through the skin

Acquired by Daiichi Sankyo 2008

Innovative cancer treatments

IPO 2007

Advanced platform technologies to enable the development of drugs
visit website

Acquired by Shire 2006

Development of drug for rare and fatal disease

IPO 2006

Highly specific detection of tumors
visit website

Acquired by Pharming 2006

Products for medical problems associated with aging

Acquired by Astra Zeneca 2006

Innovative cancer treatments

IPO 2000

Development of vaccines

IPO 1999

Commercialization of vaccines for infectious disease

Acquired by Cosmo

Novel drugs for bladder disorders and inflammatory diseases

IPO 2000

Precise identification of diseases and disorders in humans
visit website

IPO 1996

Diagnostics and laboratory testing equipment
visit website

Spontaneous growth of natural heart valves and vessels visit website

Minimally invasive treatment of bone fractures visit website

First treatment healing rotator cuff disease visit website

Ultra-rapid diagnosis of infections visit website

Prevention of drug misadministration at the bedside visit website

Minimally invasive reshaping of heart valve visit website

Treatment of improper fluid balances in the body visit website

Treatment of severe hospitalized Influenza visit website

Development of next generation biobutanol

Next-generation glucose measuring devices visit website

Advanced robotic platforms visit website

Acquired by Leica

Labeling and detection of biological molecules
visit website

Highly innovative repair of damaged knees and spinal discs visit website

Introgene

Merged with U-Bisys into Crucell

Development of vaccines

Ness

Acquired by Bioness

Innovative rehabilitation products

Quadrant

IPO

Drug formulation

Biora

Acquired by Straumann

Commercialization of products used by dentists and oral surgeons

U-Bisys

Merged with Introgene into Crucell

Innovative drug development platform